OS Therapies grants director 300,000 stock options

The 12 monthly vesting installments require continued service as a director on each vesting date.

Available on EDGAR 10/30/2026 - 08:59 PM EDT Accepted by SEC EDGAR 10/30/2026 - 08:58 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OS Therapies Inc (OSTX) director Olivier Roger Jarry received options to purchase 300,000 shares of common stock on October 22, 2026, at an exercise price of $1.25 per share. The options vest in 12 equal monthly installments on each monthly anniversary of the grant date, provided he is serving as a director on each applicable vesting date. They expire on October 22, 2036.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Jarry Olivier Roger

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy) F1	300,000	$0.00	$0.00

Holdings After Transaction: Stock options (right to buy) — 300,000 contracts (Direct)

Footnotes (1)

1. F1. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.

Key Figures

Shares underlying options: 300,000 shares Exercise price: $1.25 per share Vesting installments: 12 equal installments +1 more

4 metrics

Shares underlying options 300,000 shares Common stock covered by the options granted on October 22, 2026

Exercise price $1.25 per share Price to purchase the underlying common stock

Vesting installments 12 equal installments Monthly anniversaries of the grant date, subject to continued director service on each vesting date

Option expiration October 22, 2036 Expiration date of the options

Key Terms

stock option award agreement, incentive compensation plan, vest

3 terms

stock option award agreement financial

"terms and conditions of a stock option award agreement"

A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.

incentive compensation plan financial

"amended and restated 2023 incentive compensation plan"

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

vest financial

"These options vest in 12 equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did OSTX director Olivier Roger Jarry receive?

Olivier Roger Jarry received options to purchase 300,000 shares of OS Therapies Inc common stock on October 22, 2026, at an exercise price of $1.25 per share.

When do Olivier Roger Jarry's OSTX options vest?

The options vest in 12 equal installments on each monthly anniversary of the October 22, 2026 grant date, provided he is serving as a director on each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarry Olivier Roger

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MARYLAND 21638

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.25	10/22/2026		A		300,000		(1)	10/22/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on each applicable vesting date.

	/s/ Olivier Jarry	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)